S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Theseus Pharmaceuticals Insider Trades

+0.05 (+0.50%)
(As of 01/21/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
217,105 shs
Average Volume
154,307 shs
Market Capitalization
$385.48 million
P/E Ratio
Dividend Yield

Theseus Pharmaceuticals (NASDAQ:THRX) Insider Buying and Selling Activity

Number Of
Insiders Buying
(Last 12 Months)

Amount Of
Insider Buying
(Last 12 Months)
$1.53 M

Number Of
Insiders Selling
(Last 12 Months)

Skip Chart & View Insider Trade History

Insider Buying and Selling by Quarter

Get THRX Insider Trade Alerts

Want to know when executives and insiders are buying or selling Theseus Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

Theseus Pharmaceuticals (NASDAQ THRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/21/2022Carl L GordonDirectorBuy111,896$9.97$1,115,603.12  
1/19/2022Carl L GordonDirectorBuy11,521$9.97$114,864.37  
1/13/2022Carl L GordonDirectorBuy17,320$9.43$163,327.60  
1/11/2022Carl L GordonDirectorBuy8,500$10.51$89,335.00  
12/21/2021Bradford D DahmsCFOBuy1,970$10.15$19,995.50  
12/21/2021Timothy P ClacksonCEOBuy2,600$9.76$25,376.00  
(Data available from 1/1/2013 forward)

Theseus Pharmaceuticals (NASDAQ:THRX) Insider Trade Frequently Asked Questions

Who is on Theseus Pharmaceuticals's Insider Roster?

The list of insiders at Theseus Pharmaceuticals includes Bradford D Dahms, Carl L Gordon, and Timothy P Clackson.Learn more on THRX's insiders

Which Theseus Pharmaceuticals insiders have been buying company stock?

The following insiders have purchased Theseus Pharmaceuticals stock in the last 24 months: Bradford D Dahms ($19,995.50), Carl L Gordon ($1,483,130.09), and Timothy P Clackson ($25,376.00).

How much insider buying is happening at Theseus Pharmaceuticals?

Insiders have purchased a total of 153,807 Theseus Pharmaceuticals shares in the last 24 months for a total of $1,528,501.59 bought.

This page was last updated on 1/23/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.